rentradВестник рентгенологии и радиологииJournal of radiology and nuclear medicine0042-46762619-0478Limited Liability Company "LUCHEVAYA DIAGNOSTIKA", Russian Association of Radiologists10.20862/0042-4676-2020-101-4-221-234rentrad-573Research ArticleОБЗОРЫREVIEWSРоль методов радионуклидной диагностики в нейроонкологииThe Role of Radionuclide Diagnostic Methods in Neuro-Oncologyhttps://orcid.org/0000-0003-0392-7576СкворцоваТ. Ю.SkvortsovaT. Yu.

Cand. Med. Sc., Leading Researcher of Neurovisualization Laboratory, Radiologis

ul. Akademika Pavlova, 9, Saint-Petersburg, 197376, Russian Federation

tanya@ihb.spb.ruhttps://orcid.org/0000-0002-3909-9306JudovN.JudovN.

бакалаврWilhelm-Johnen-Straße, D-52425 Jülich, Germany

Templergraben 55, 52062 Aachen, Germany

Bachelor of Science

Wilhelm-Johnen-Straße, D-52425 Jülich, Germany

Templergraben 55, 52062 Aachen, Germany

https://orcid.org/0000-0002-2477-4591PlotkinM.PlotkinM.

Dr. Med. Sc., Professor

Landsberger Allee 49, 10249 Berlin, Germany

https://orcid.org/0000-0001-7114-1941StoffelsG.StoffelsG.

д. м. н., Wilhelm-Johnen-Straße, D-52425 Jülich, Germany

Wilhelm-Johnen-Straße, D-52425 Jülich, Germany

https://orcid.org/0000-0002-2485-1796GalldiksN.GalldiksN.

д. м. н., доктор философии, профессорWilhelm-Johnen-Straße, D-52425 Jülich, Germany

Kerpener 62, 50937 Köln, Germany

Wilhelm-Johnen-Straße, D-52425 Jülich, Germany

 

Kerpener 62, 50937 Köln, Germany

https://orcid.org/0000-0002-4201-7949КрасиковаР. Н.KrasikovaR. N.

Cand. Chem. Sc., Head of Radiochemistry Laboratory

ul. Akademika Pavlova, 9, Saint-Petersburg, 197376, Russian Federation

https://orcid.org/0000-0003-1101-5075LangenK. J.LangenK. J.

д. м. н., доктор философии, профессор

Wilhelm-Johnen-Straße, D-52425 Jülich, Germany

Templergraben 55, 52062 Aachen, Germany

Wilhelm-Johnen-Straße, 52425 Jülich, Germany

Dr. Med. Sc., Professor

Wilhelm-Johnen-Straße, D-52425 Jülich, Germany

Templergraben 55, 52062 Aachen, Germany

Wilhelm-Johnen-Straße, 52425 Jülich, Germany

ФГБУН «Институт мозга человека им. Н.П. Бехтеревой» Российской академии наукРоссияBechtereva Institute of the Human Brain, Russian Academy of Sciences,Russian FederationИнститут нейронаук и ядерной медицины, научный центр Юлиха; Университет Ахена, отдел ядерной медициныГерманияInstitute of Neuroscience and Medicine, Jülich Research Centre; Department of Nuclear Medicine, RWTH University of AachenGermanyИнститут ядерной медицины ВивантесаГерманияVivantes Institute of Nuclear MedicineGermanyИнститут нейронаук и ядерной медицины, научный центр ЮлихаГерманияInstitute of Neuroscience and Medicine, Jülich Research CentreGermanyИнститут нейронаук и ядерной медицины, научный центр Юлиха; Кельнский университет, отдел неврологии,ГерманияInstitute of Neuroscience and Medicine, Jülich Research Centre; Department of Neurology, University of CologneGermanyФГБУН «Институт мозга человека им. Н.П. Бехтеревой» Российской академии наукРоссияBechtereva Institute of the Human Brain, Russian Academy of SciencesRussian FederationИнститут нейронаук и ядерной медицины, научный центр Юлиха; Университет Ахена, отдел ядерной медицины; Исследовательское объединение Юлих–Ахен (ИОЮА), секция «Мозг»ГерманияInstitute of Neuroscience and Medicine, Jülich Research Centre; Department of Nuclear Medicine, RWTH University of Aachen; Jülich–Aachen Research Alliance (JARA), Section BrainGermany2020040920201014221234Copyright &#x00A9; Скворцова Т.Ю., Judov N., Plotkin M., Stoffels G., Galldiks N., Красикова Р.Н., Langen K.J., 20202020Скворцова Т.Ю., Judov N., Plotkin M., Stoffels G., Galldiks N., Красикова Р.Н., Langen K.J.Skvortsova T.Y., Judov N., Plotkin M., Stoffels G., Galldiks N., Krasikova R.N., Langen K.J.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.russianradiology.ru/jour/article/view/573обзорпозитронно-эмиссионная томографияоднофотонная эмиссионная компьютерная томографияопухоли головного мозгарадиофармпрепараты класса аминокислотO-(2’-18F-фторэтил)-L-тирозин68Ga-DOTATOCreviewpositron emission tomographysingle-photon emission computed tomographybrain tumorsamino acid radiopharmaceuticalsO-(2-[18F] fluoroethyl)-L-tyrosine (FET)[68Ga]DOTATOCReferencesOstrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014; 16 (Suppl 4): PMC4193675. doi: 10.1093/neuonc/nou223Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014; 16 (Suppl 4): PMC4193675. doi: 10.1093/neuonc/nou223Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Pep. 2012; 14: 48–54. doi: 10.1007/s11912-011-0203-yNayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Pep. 2012; 14: 48–54. doi: 10.1007/s11912-011-0203-yWeller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014; 15(9): 395–403. doi: 10.1016/S1470-2045(14)70011-7Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014; 15(9): 395–403. doi: 10.1016/S1470-2045(14)70011-7Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009; 22(6): 6338. doi: 10.1097/WCO.0b013e328332363eBrandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009; 22(6): 6338. doi: 10.1097/WCO.0b013e328332363eRapp M, Heinzel A, Galldiks N, Stoffels G, Feisberg J, Sabel M, et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med. 2013; 54(2): 229–35. doi: 10.2967/jnumed.112.109603Rapp M, Heinzel A, Galldiks N, Stoffels G, Feisberg J, Sabel M, et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med. 2013; 54(2): 229–35. doi: 10.2967/jnumed.112.109603Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol. 2015; 17(9): 1293– 300. doi: 10.1093/neuonc/nov088Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol. 2015; 17(9): 1293– 300. doi: 10.1093/neuonc/nov088Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007; 48(9): 1468–81. doi: 10.2967/jnumed.106.037689Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007; 48(9): 1468–81. doi: 10.2967/jnumed.106.037689Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, et al. Prediction of pathology and survival by FDG-PET in gliomas. J Neurooncol. 2003; 64(3): 227–37. doi: 10.1023/A: 1025665820001Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, et al. Prediction of pathology and survival by FDG-PET in gliomas. J Neurooncol. 2003; 64(3): 227–37. doi: 10.1023/A: 1025665820001Yoon JH, Kim JH, Kang WJ, Sohn CH, Choi SH, Yun TJ, et al. Grading of cerebral glioma with multiparametric MR imaging and 18F-FDG-PET: concordance and accuracy. Eur Radiol. 2014; 24(2): 380–9. doi: 10.1007/s00330-013-3019-3Yoon JH, Kim JH, Kang WJ, Sohn CH, Choi SH, Yun TJ, et al. Grading of cerebral glioma with multiparametric MR imaging and 18F-FDG-PET: concordance and accuracy. Eur Radiol. 2014; 24(2): 380–9. doi: 10.1007/s00330-013-3019-3Prieto E, Marti-Climent JM, Dominguez-Prado I, Garrastachu P, Díez-Valle R, Tejada S, et al. Voxel-based analysis of dual-timepoint 18F-FDG PET images for brain tumor identification and delineation. J Nucl Med. 2011; 52(6): 865–72. doi: 10.2967/jnumed.110.085324Prieto E, Marti-Climent JM, Dominguez-Prado I, Garrastachu P, Díez-Valle R, Tejada S, et al. Voxel-based analysis of dual-timepoint 18F-FDG PET images for brain tumor identification and delineation. J Nucl Med. 2011; 52(6): 865–72. doi: 10.2967/jnumed.110.085324DeWitte O, Levivier M, Violon P, Salmon I. Prognostic value positron emission tomography with [18F]-fluoro-2- deoxy-D-glucose in the low-grade glioma. J Neurosurg. 1996; 39(3): 470–6. doi: 10.1097/00006123-199609000-00007DeWitte O, Levivier M, Violon P, Salmon I. Prognostic value positron emission tomography with [18F]-fluoro-2- deoxy-D-glucose in the low-grade glioma. J Neurosurg. 1996; 39(3): 470–6. doi: 10.1097/00006123-199609000-00007Glantz MJ, Hoffman JM, Coleman RE, Friedman AH, Hanson MW, Burger PC, et al. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol. 1991; 29(4): 347–55. doi: 10.1002/ana.410290403Glantz MJ, Hoffman JM, Coleman RE, Friedman AH, Hanson MW, Burger PC, et al. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol. 1991; 29(4): 347–55. doi: 10.1002/ana.410290403Basu S, Alavi A. Molecular imaging (PET) of brain tumors. Neuroimaging Clin N Am. 2009; 19(4): 625–46. doi: 10.1016/j.nic.2009.08.012Basu S, Alavi A. Molecular imaging (PET) of brain tumors. Neuroimaging Clin N Am. 2009; 19(4): 625–46. doi: 10.1016/j.nic.2009.08.012Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? Am J Neurorad. 1998; 19(3): 407–13.Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? Am J Neurorad. 1998; 19(3): 407–13.Galldiks N, Langen KJ. Applications of PET imaging of neurological tumors with radiolabeled amino acids. Q J Nucl Med Mol Imaging. 2015; 59(1): 70–82.Galldiks N, Langen KJ. Applications of PET imaging of neurological tumors with radiolabeled amino acids. Q J Nucl Med Mol Imaging. 2015; 59(1): 70–82.Fedorova O, Kuznetsova O, Stepanova M, Maleev V, Belokon Yu, Wester HJ, еt al. A facile direct nucleophilic synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine([18F]FET) without HPLC purification. J Rad Nucl Chem. 2014; 301: 505–12. doi: 10.1007/s10967-014-3121-2.Fedorova O, Kuznetsova O, Stepanova M, Maleev V, Belokon Yu, Wester HJ, еt al. A facile direct nucleophilic synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine([18F]FET) without HPLC purification. J Rad Nucl Chem. 2014; 301: 505–12. doi: 10.1007/s10967-014-3121-2.Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, et al. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006; 33(3): 287–94. doi: 10.1016/j.nucmedbio.2006.01.002Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, et al. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006; 33(3): 287–94. doi: 10.1016/j.nucmedbio.2006.01.002Kratochwil C, Combs SE, Leotta K, Afshar-Oromieh A, Rieken S, Debus J, et al. Intra-individual comparison of (1)(8)F-FET and (1)(8)F-DOPA in PET imaging of recurrent brain tumors. Neuro Oncol. 2014; 16(3): 434–40. doi: 10.1093/neuonc/not199Kratochwil C, Combs SE, Leotta K, Afshar-Oromieh A, Rieken S, Debus J, et al. Intra-individual comparison of (1)(8)F-FET and (1)(8)F-DOPA in PET imaging of recurrent brain tumors. Neuro Oncol. 2014; 16(3): 434–40. doi: 10.1093/neuonc/not199Moulin-Romsee G, D’Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L, et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging. 2007; 34(12): 2082–7. doi: 10.1007/s00259-007-0557-4Moulin-Romsee G, D’Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L, et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging. 2007; 34(12): 2082–7. doi: 10.1007/s00259-007-0557-4Cicone F, Filss CP, Minniti G, Rossi-Espagnet C, Papa A, Scaringi K, et al. Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI. Eur J Nucl Med Mol Imaging. 2015; 42(6): 905–15. doi: 10.1007/s00259-015-3018-5Cicone F, Filss CP, Minniti G, Rossi-Espagnet C, Papa A, Scaringi K, et al. Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI. Eur J Nucl Med Mol Imaging. 2015; 42(6): 905–15. doi: 10.1007/s00259-015-3018-5Galldiks N, Langen KJ, Pope WB. From the clinician’s point of view – What is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol. 2015; 17(11): 1434–44. doi: 10.1093/neuonc/nov118Galldiks N, Langen KJ, Pope WB. From the clinician’s point of view – What is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol. 2015; 17(11): 1434–44. doi: 10.1093/neuonc/nov118Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot. 2002; 57(6): 853–6. doi: 10.1016/S0969-8043(02)00225-7Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot. 2002; 57(6): 853–6. doi: 10.1016/S0969-8043(02)00225-7Krasikova R, Orlovskaya V, Stepanova M, Fedorova O. The effect of reaction media and phase transfer catalyst on the fluorination yield and enantiomeric purity in asymmetric synthesis of O-(2’-[18F]fluoroethyl)-L-tyrosine. Curr Org Chem. 2013; 17(19): 2159–63. doi: 10.2174/13852728113179990108Krasikova R, Orlovskaya V, Stepanova M, Fedorova O. The effect of reaction media and phase transfer catalyst on the fluorination yield and enantiomeric purity in asymmetric synthesis of O-(2’-[18F]fluoroethyl)-L-tyrosine. Curr Org Chem. 2013; 17(19): 2159–63. doi: 10.2174/13852728113179990108Hutterer M, Hau P, Langen KJ, Galldiks N. Pitfalls of [F18]-FET PET in the diagnostics of brain tumors. Der Nuklearmediziner. 2015; 38(4): 295–303. doi: 10.1055/s-0035-1564177Hutterer M, Hau P, Langen KJ, Galldiks N. Pitfalls of [F18]-FET PET in the diagnostics of brain tumors. Der Nuklearmediziner. 2015; 38(4): 295–303. doi: 10.1055/s-0035-1564177Herholz K, Hölzer T, Bauer B, Schröder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of lowgrade gliomas. Neurology. 1998; 50(5): 1316–22. doi: 10.1212/wnl.50.5.1316Herholz K, Hölzer T, Bauer B, Schröder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of lowgrade gliomas. Neurology. 1998; 50(5): 1316–22. doi: 10.1212/wnl.50.5.1316Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016; 18(9): 1199–208. doi: 10.1093/neuonc/now058Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016; 18(9): 1199–208. doi: 10.1093/neuonc/now058Langen KJ, Watts C. Neuro-oncology: amino acid PET for brain tumours – ready for the clinic? Nature Reviews Neurology. 2016; 12(7): 375–6. doi: 10.1038/nrneurol.2016.80Langen KJ, Watts C. Neuro-oncology: amino acid PET for brain tumours – ready for the clinic? Nature Reviews Neurology. 2016; 12(7): 375–6. doi: 10.1038/nrneurol.2016.80Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K, Firsching R, Höllt V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent over expression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000; 6(5): 1865–74.Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K, Firsching R, Höllt V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent over expression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000; 6(5): 1865–74.Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, Patel YC. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998; 76(5): 620–7. doi: 10.1002/(SICI)1097-0215(19980529)76: 5<620: : AID-IJC2>3.0.CO; 2-SDutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, Patel YC. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998; 76(5): 620–7. doi: 10.1002/(SICI)1097-0215(19980529)76: 5<620: : AID-IJC2>3.0.CO; 2-SHenze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, et al. PET imaging of somatostatin receptors using [68GA]-DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med. 2001; 42(7): 1053–6.Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, et al. PET imaging of somatostatin receptors using [68GA]-DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med. 2001; 42(7): 1053–6.Soto-Montenegro ML, Peña-Zalbidea S, Mateos-Pérez JM, Oteo M, Romero E, Morcillo MÁ, Desco M. Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice. PLoS One. 2014; 9(11): e111624. doi: 10.1371/journal.pone.0111624Soto-Montenegro ML, Peña-Zalbidea S, Mateos-Pérez JM, Oteo M, Romero E, Morcillo MÁ, Desco M. Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice. PLoS One. 2014; 9(11): e111624. doi: 10.1371/journal.pone.0111624Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012; 39(9): 1409–15. doi: 10.1007/s00259-012-2155-3Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012; 39(9): 1409–15. doi: 10.1007/s00259-012-2155-3Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Pöschl J, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015; 56(3): 347–53. doi: 10.2967/jnumed.114.149120Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Pöschl J, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015; 56(3): 347–53. doi: 10.2967/jnumed.114.149120Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, et al. Improved target volume definition for fractionated stereotacticradiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]- DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006; 65(1): 222–7. doi: 10.1016/j.ijrobp.2005.12.006Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, et al. Improved target volume definition for fractionated stereotacticradiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]- DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006; 65(1): 222–7. doi: 10.1016/j.ijrobp.2005.12.006Nyuyki F, Plotkin M, Graf R, Michel R, Steffen I, Denecke T, et al. Potential impact of(68)Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas. Eur J Nucl Med Mol Imaging. 2010; 37(2): 310–8. doi: 10.1007/s00259-009-1270-2Nyuyki F, Plotkin M, Graf R, Michel R, Steffen I, Denecke T, et al. Potential impact of(68)Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas. Eur J Nucl Med Mol Imaging. 2010; 37(2): 310–8. doi: 10.1007/s00259-009-1270-2Graf R, Nyuyki F, Steffen IG, Michel R, Fahdt D, Wust P, et al. Contribution of(68)Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy. Int J Radiat Oncol Biol Phys. 2013; 85(1): 68–73. doi: 10.1016/j.ijrobp.2012.03.021Graf R, Nyuyki F, Steffen IG, Michel R, Fahdt D, Wust P, et al. Contribution of(68)Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy. Int J Radiat Oncol Biol Phys. 2013; 85(1): 68–73. doi: 10.1016/j.ijrobp.2012.03.021Graf R, Plotkin M, Steffen IG, Wurm R, Wust P, Brenner W, et al. Magnetic resonance imaging, computed tomography, and 68GaDOTATOC positron emission tomography for imaging skull base meningiomas with infracranial extension treated with stereotactic radiotherapy – a case series. Head Face Med. 2012; 8: 1. doi: 10.1186/1746-160X-8-1Graf R, Plotkin M, Steffen IG, Wurm R, Wust P, Brenner W, et al. Magnetic resonance imaging, computed tomography, and 68GaDOTATOC positron emission tomography for imaging skull base meningiomas with infracranial extension treated with stereotactic radiotherapy – a case series. Head Face Med. 2012; 8: 1. doi: 10.1186/1746-160X-8-1Gehler B, Paulsen F, Oksüz MO, Hauser TK, Eschmann SM, Bares R, et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009; 4: 56. doi: 10.1186/1748-717X-4-56Gehler B, Paulsen F, Oksüz MO, Hauser TK, Eschmann SM, Bares R, et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009; 4: 56. doi: 10.1186/1748-717X-4-56Combs SE, Welzel T, Habermehl D, Rieken S, Dittmar JO, Kessel K, et al. Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET. Acta Oncol. 2013; 52(3): 514–20. doi: 10.3109/0284186X.2013.762996Combs SE, Welzel T, Habermehl D, Rieken S, Dittmar JO, Kessel K, et al. Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET. Acta Oncol. 2013; 52(3): 514–20. doi: 10.3109/0284186X.2013.762996Schillaci O, Filippi L, Manni C, Santoni R. Single-photon emission computed tomography/computed tomography in brain tumors. Semin Nucl Med. 2007; 37(1): 34–47. doi: 10.1053/j.semnuclmed.2006.08.003Schillaci O, Filippi L, Manni C, Santoni R. Single-photon emission computed tomography/computed tomography in brain tumors. Semin Nucl Med. 2007; 37(1): 34–47. doi: 10.1053/j.semnuclmed.2006.08.003Hellwig D, Ketter R, Romeike BF, Schaefer A, Farmakis G, Grgic A, et al. Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma. Eur J Nucl Med Mol Imaging. 2010; 37(12): 2344–53. doi: 10.1007/s00259-010-1572-4Hellwig D, Ketter R, Romeike BF, Schaefer A, Farmakis G, Grgic A, et al. Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma. Eur J Nucl Med Mol Imaging. 2010; 37(12): 2344–53. doi: 10.1007/s00259-010-1572-4Langen KJ, Pauleit D, Coenen HH. 3-[(123)I]Iodo-alpha-methyl-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2002; 29(6): 625–31. doi: 10.1016/S0969-8051(02)00328-1Langen KJ, Pauleit D, Coenen HH. 3-[(123)I]Iodo-alpha-methyl-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2002; 29(6): 625–31. doi: 10.1016/S0969-8051(02)00328-1Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, et al. Somatostatin receptor imaging in intracranial tumors. Eur J Nucl Med. 1998; 25(7): 675–86.Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, et al. Somatostatin receptor imaging in intracranial tumors. Eur J Nucl Med. 1998; 25(7): 675–86.Bohuslavizki KH, Brenner W, Braunsdorf WE, Behnke A, Tinnemeyer S, Hugo HH, et al. Somatostatin receptor scintigraphy in the differential diagnosis of meningioma. Nucl Med Commun. 1996; 17(4): 302–10.Bohuslavizki KH, Brenner W, Braunsdorf WE, Behnke A, Tinnemeyer S, Hugo HH, et al. Somatostatin receptor scintigraphy in the differential diagnosis of meningioma. Nucl Med Commun. 1996; 17(4): 302–10.Collet S, Valable S, Constans JM, Lechapt-Zalcman E, Roussel S, Delcroix N, et al. [(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas. NeuroImage Clin. 2015; 8: 448–54. doi: 10.1016/j.nicl.2015.05.012Collet S, Valable S, Constans JM, Lechapt-Zalcman E, Roussel S, Delcroix N, et al. [(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas. NeuroImage Clin. 2015; 8: 448–54. doi: 10.1016/j.nicl.2015.05.012Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, et al. 11C-methionine(MET) and 18F-fluorothymidine(FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging. 2008; 35(11): 2009–17. doi: 10.1007/s00259-008-0847-5Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, et al. 11C-methionine(MET) and 18F-fluorothymidine(FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging. 2008; 35(11): 2009–17. doi: 10.1007/s00259-008-0847-5Nowosielski M, DiFranco MD, Putzer D, Seiz M, Recheis W, Jacobs AH, et al. An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoS ONE. 2014; 9(4): e95830. doi: 10.1371/journal.pone.0095830Nowosielski M, DiFranco MD, Putzer D, Seiz M, Recheis W, Jacobs AH, et al. An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoS ONE. 2014; 9(4): e95830. doi: 10.1371/journal.pone.0095830Giovannini E, Lazzeri P, Milano A, Gaeta MC, Ciarmiello A. Clinical applications of choline PET/CT in brain tumors. Curr Pharm Des. 2015; 21(1): 121–7. doi: 10.2174/1381612820666140915120742Giovannini E, Lazzeri P, Milano A, Gaeta MC, Ciarmiello A. Clinical applications of choline PET/CT in brain tumors. Curr Pharm Des. 2015; 21(1): 121–7. doi: 10.2174/1381612820666140915120742Ohtani T, Kurihara H, Ishiuchi S, Saito N, Oriuchi N, Inoue T, Sasaki T. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med. 2001; 28(11): 1664–70. DOI: 10.1007/s002590100620Ohtani T, Kurihara H, Ishiuchi S, Saito N, Oriuchi N, Inoue T, Sasaki T. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med. 2001; 28(11): 1664–70. DOI: 10.1007/s002590100620Sollini M, Sghedoni R, Erba PA, Cavuto S, Froio A, De Berti G, et al. Diagnostic performances of [18f]fluorocholine positron emission tomography in brain tumors. Q J Nucl Med Mol Imaging. 2015; 62(2): 209–19. doi: 10.23736/S1824-4785.17.02807-2Sollini M, Sghedoni R, Erba PA, Cavuto S, Froio A, De Berti G, et al. Diagnostic performances of [18f]fluorocholine positron emission tomography in brain tumors. Q J Nucl Med Mol Imaging. 2015; 62(2): 209–19. doi: 10.23736/S1824-4785.17.02807-2Kobayashi H, Hirata K, Yamaguchi S, Terasaka S, Shiga T, Houkin K. Usefulness of FMISO-PET for glioma analysis. Neurol Med Chir. 2013; 53(11): 773–8. doi: 10.2176/nmc.ra2013-0256Kobayashi H, Hirata K, Yamaguchi S, Terasaka S, Shiga T, Houkin K. Usefulness of FMISO-PET for glioma analysis. Neurol Med Chir. 2013; 53(11): 773–8. doi: 10.2176/nmc.ra2013-0256Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al. [18F]-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malig nant gliomas. Eur J Nucl Med Mol Imaging. 2012; 39(5): 760–70. doi: 10.1007/s00259-011-2037-0Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al. [18F]-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malig nant gliomas. Eur J Nucl Med Mol Imaging. 2012; 39(5): 760–70. doi: 10.1007/s00259-011-2037-0Winkeler A, Boisgard R, Awde AR, Dubois A, Thézé B, Zheng J, et al. The translocator protein ligand [18F]DPA-714 images glioma and activated microglia in vivo. Eur J Nucl Med Mol Imaging. 2012; 39(5): 811–23. doi: 10.1007%2Fs00259- 011-2041-4Winkeler A, Boisgard R, Awde AR, Dubois A, Thézé B, Zheng J, et al. The translocator protein ligand [18F]DPA-714 images glioma and activated microglia in vivo. Eur J Nucl Med Mol Imaging. 2012; 39(5): 811–23. doi: 10.1007%2Fs00259- 011-2041-4Jensen P, Feng L, Law I, Svarer C, Knudsen GM, Mikkelsen JD, et al. TSPO imaging in glioblastoma multiforme: a direct comparison between 123I-CLINDE SPECT, 18F-FET PET, and gadolinium-enhanced MR imaging. J Nucl Med. 2015; 56(9): 1386–90. doi: 10.2967/jnumed.115.158998Jensen P, Feng L, Law I, Svarer C, Knudsen GM, Mikkelsen JD, et al. TSPO imaging in glioblastoma multiforme: a direct comparison between 123I-CLINDE SPECT, 18F-FET PET, and gadolinium-enhanced MR imaging. J Nucl Med. 2015; 56(9): 1386–90. doi: 10.2967/jnumed.115.158998Smits A, Baumert BG. The clinical value of PET with amino acid tracers for gliomas WHO grade II. Int J Mol Imaging. 2011; 2011: 372509. doi: 10.1155/2011/372509Smits A, Baumert BG. The clinical value of PET with amino acid tracers for gliomas WHO grade II. Int J Mol Imaging. 2011; 2011: 372509. doi: 10.1155/2011/372509Smits A, Westerberg E, Ribom D. Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas. Eur J Nucl Med Mol Imaging. 2008; 35(1): 65–71. doi: 10.1007/s00259-007-0531-1Smits A, Westerberg E, Ribom D. Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas. Eur J Nucl Med Mol Imaging. 2008; 35(1): 65–71. doi: 10.1007/s00259-007-0531-1Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, et al. Comparison of(18)F-FET and(18)F-FDG PET in brain tumors. Nucl Med Biol. 2009; 36(7): 779–87. doi: 10.1016/j.nucmedbio.2009.05.005Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, et al. Comparison of(18)F-FET and(18)F-FDG PET in brain tumors. Nucl Med Biol. 2009; 36(7): 779–87. doi: 10.1016/j.nucmedbio.2009.05.005Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, et al. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg. 2004; 101(3): 476–83. doi: 10.3171/jns.2004.101.3.0476Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, et al. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg. 2004; 101(3): 476–83. doi: 10.3171/jns.2004.101.3.0476Plotkin M, Blechschmidt C, Auf G, Nyuyki F, Geworski L, Denecke T, et al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur Radiol. 2010; 20: 2496–502. doi: 10.1007/s00330-010-1819-2Plotkin M, Blechschmidt C, Auf G, Nyuyki F, Geworski L, Denecke T, et al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur Radiol. 2010; 20: 2496–502. doi: 10.1007/s00330-010-1819-2Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G, et al. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med. 2013; 54(12): 2046–54. doi: 10.2967/jnumed.113.123836Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G, et al. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med. 2013; 54(12): 2046–54. doi: 10.2967/jnumed.113.123836Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S, et al. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med. 2015; 56(1): 9–15. doi: 10.2967/jnumed.114.144675Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S, et al. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med. 2015; 56(1): 9–15. doi: 10.2967/jnumed.114.144675Unterrainer M, Schweisthal F, Suchorska B, Wenter V, SchmidTannwald C, Fendler WP, et al. Serial 18F-FET P imaging of primarily 18F-FET-negative glioma – does it make sense? J Nucl Med. 2016; 57(8): 1177–82. doi: 10.2967/jnumed.115.171033Unterrainer M, Schweisthal F, Suchorska B, Wenter V, SchmidTannwald C, Fendler WP, et al. Serial 18F-FET P imaging of primarily 18F-FET-negative glioma – does it make sense? J Nucl Med. 2016; 57(8): 1177–82. doi: 10.2967/jnumed.115.171033Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004; 10(21): 7163–70. doi: 10.1158/1078-0432.CCR-04-0262Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004; 10(21): 7163–70. doi: 10.1158/1078-0432.CCR-04-0262Lopez WO, Cordeiro JG, Albicker U, Doostkam S, Nikkhah G, Kirch RD, et al. Correlation of(18)F-fluoroethyl tyrosine positronemission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool. Onco Targets Ther. 2015; 8: 3803–15. doi: 10.2147/OTT.S87126Lopez WO, Cordeiro JG, Albicker U, Doostkam S, Nikkhah G, Kirch RD, et al. Correlation of(18)F-fluoroethyl tyrosine positronemission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool. Onco Targets Ther. 2015; 8: 3803–15. doi: 10.2147/OTT.S87126Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins VP, Bergström M, et al. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol. 1989; 30(3): 225–32.Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins VP, Bergström M, et al. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol. 1989; 30(3): 225–32.Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Müller HW, et al. O-(2-[18F]fluoroethyl)-L- tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005; 128(3): 678–87. doi: 10.1093/brain/awh399Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Müller HW, et al. O-(2-[18F]fluoroethyl)-L- tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005; 128(3): 678–87. doi: 10.1093/brain/awh399Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, et al. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery. 2009; 64(3): 471–81. doi: 10.1227/01.NEU.0000338949.94496.85Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, et al. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery. 2009; 64(3): 471–81. doi: 10.1227/01.NEU.0000338949.94496.85Buchmann N, Klasner B, Gempt J, Bauer JS, Pyka T, Delbridge C, et al. (18)F-fluoroethyl-l-thyrosine positron emission tomography to delineate tumor residuals after glioblastoma resection: a comparison with standard postoperative magnetic resonance imaging. World Neurosurg. 2016; 89: 420–6. doi: 10.1016/j.wneu.2016.02.032Buchmann N, Klasner B, Gempt J, Bauer JS, Pyka T, Delbridge C, et al. (18)F-fluoroethyl-l-thyrosine positron emission tomography to delineate tumor residuals after glioblastoma resection: a comparison with standard postoperative magnetic resonance imaging. World Neurosurg. 2016; 89: 420–6. doi: 10.1016/j.wneu.2016.02.032Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, et al. Prognostic impact of postoperative, pre-irradiation(18)Ffluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol. 2011; 99(2): 218–24. doi: 10.1016/j.radonc.2011.03.006Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, et al. Prognostic impact of postoperative, pre-irradiation(18)Ffluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol. 2011; 99(2): 218–24. doi: 10.1016/j.radonc.2011.03.006Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, et al. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 2015; 84(7): 710–9. doi: 10.1212/WNL.0000000000001262Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, et al. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 2015; 84(7): 710–9. doi: 10.1212/WNL.0000000000001262Grosu AL, Weber WA. PET for radiation treatment planning of brain tumours. Radiother Oncol. 2010; 96(3): 325–7. doi: 10.1016/j.radonc.2010.08.001Grosu AL, Weber WA. PET for radiation treatment planning of brain tumours. Radiother Oncol. 2010; 96(3): 325–7. doi: 10.1016/j.radonc.2010.08.001Rosenschold PM, Costa J, Engelholm SA, Lundemann MJ, Law I, Ohlhues L, Engelholm S. Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of highgrade glioma. Neuro Oncol. 2015; 17(5): 757–63. doi: 10.1093/neuonc/nou316Rosenschold PM, Costa J, Engelholm SA, Lundemann MJ, Law I, Ohlhues L, Engelholm S. Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of highgrade glioma. Neuro Oncol. 2015; 17(5): 757–63. doi: 10.1093/neuonc/nou316Piroth MD, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G, et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. Strahlenther Onkol. 2012; 188(4): 334–9. doi: 10.1007/s00066-011-0060-5Piroth MD, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G, et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. Strahlenther Onkol. 2012; 188(4): 334–9. doi: 10.1007/s00066-011-0060-5Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D, et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med. 2004; 45(7): 1146–54.Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D, et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med. 2004; 45(7): 1146–54.Rickhey M, Koelbl O, Eilles C, Bogner L. A biologically adapted dose-escalation approach, demonstrated for 18F-FET- PET in brain tumors. Strahlenther Onkol. 2008; 184(10): 536–42. doi: 10.1007/s00066-008-1883-6Rickhey M, Koelbl O, Eilles C, Bogner L. A biologically adapted dose-escalation approach, demonstrated for 18F-FET- PET in brain tumors. Strahlenther Onkol. 2008; 184(10): 536–42. doi: 10.1007/s00066-008-1883-6Rieken S, Habermehl D, Giesel FL, Hoffmann C, Burger U, Rief H, et al. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy. Radiother Oncol. 2013; 109(3): 487–92. doi: 10.1016/j.radonc.2013.06.043Rieken S, Habermehl D, Giesel FL, Hoffmann C, Burger U, Rief H, et al. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy. Radiother Oncol. 2013; 109(3): 487–92. doi: 10.1016/j.radonc.2013.06.043Weber DC, Zilli T, Buchegger F, Casanova N, Haller G, Rouzaud M, et al. [(18)F]Fluoroethyltyrosine-positron emission tomographyguided radiotherapy for high-grade glioma. Radiat Oncol. 2008; 3: 44. doi: 10.1186/1748-717X-3-44Weber DC, Zilli T, Buchegger F, Casanova N, Haller G, Rouzaud M, et al. [(18)F]Fluoroethyltyrosine-positron emission tomographyguided radiotherapy for high-grade glioma. Radiat Oncol. 2008; 3: 44. doi: 10.1186/1748-717X-3-44Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol. 2016; 18(3): 426–34. doi: 10.1093/neuonc/nov148Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol. 2016; 18(3): 426–34. doi: 10.1093/neuonc/nov148Manabe O, Hattori N, Yamaguchi S, Hirata K, Kobayaxhi K, Terasaka S, et al. Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging. Eur J Nucl Med Mol Imaging. 2015; 42(6): 896–904. doi: 10.1007/s00259-015-2996-7Manabe O, Hattori N, Yamaguchi S, Hirata K, Kobayaxhi K, Terasaka S, et al. Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging. Eur J Nucl Med Mol Imaging. 2015; 42(6): 896–904. doi: 10.1007/s00259-015-2996-7Pöpperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007; 34(12): 1933–42. doi: 10.1007/s00259-007-0534-yPöpperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007; 34(12): 1933–42. doi: 10.1007/s00259-007-0534-yStockhammer F, Plotkin M, Amthauer H, van Landeghem FK, Woiciechowsky C. Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neurooncol. 2008; 88(2): 205–10. doi: 10.1007/s11060-008-9551-3Stockhammer F, Plotkin M, Amthauer H, van Landeghem FK, Woiciechowsky C. Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neurooncol. 2008; 88(2): 205–10. doi: 10.1007/s11060-008-9551-3Wyss MT, Hofer S, Hefti M, Bärtschi E, Uhlmann C, Treyer V, Roelcke U. Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake. J Nucl Med. 2007; 48(7): 1047–52. doi: 10.2967/jnumed.106.038489Wyss MT, Hofer S, Hefti M, Bärtschi E, Uhlmann C, Treyer V, Roelcke U. Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake. J Nucl Med. 2007; 48(7): 1047–52. doi: 10.2967/jnumed.106.038489Скворцова Т.Ю., Захс Д.В., Гурчин А.Ф. ПЭТ с [11С]-метионином в диагностике глиальных опухолей головного мозга. Вестник РОНЦ им. Н.Н. Блохина. 2016; 27(4): 61–9.Skvortsova TYu, Zakhs DV, Gurchin AF. PET using [11C]methionine for assessment of cerebral gliomas. Journal of Blokhin Russian Cancer Research Center. 2016: 27(4): 61–9 (in Russian).Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A, et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine(F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med. 2011; 36(10): 841–7. doi: 10.1097/RLU.0b013e3182291b40Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A, et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine(F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med. 2011; 36(10): 841–7. doi: 10.1097/RLU.0b013e3182291b40Weckesser M, Langen KJ, Rickert CH, Kloska S, Straeter R, Hamacher K, et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging. 2005; 32(4): 422–9. doi: 10.1007/s00259-004-1705-8Weckesser M, Langen KJ, Rickert CH, Kloska S, Straeter R, Hamacher K, et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging. 2005; 32(4): 422–9. doi: 10.1007/s00259-004-1705-8Albert NL, Winkelmann I, Suchorska B, Wenter V, Schmid-Tannwald C, Mille E, et al. Early static(18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans. Eur J Nucl Med Mol Imaging. 2016; 43(6): 1105–14. doi: 10.1007/s00259-015-3276-2Albert NL, Winkelmann I, Suchorska B, Wenter V, Schmid-Tannwald C, Mille E, et al. Early static(18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans. Eur J Nucl Med Mol Imaging. 2016; 43(6): 1105–14. doi: 10.1007/s00259-015-3276-2Galldiks N, Dunkl V, Kracht LW, Vollmar S, Jacobs AH, Fink GR, et al. Volumetry of [(1)(1)C]-methionine positron emission tomographic uptake as a prognostic marker before treatment of patients with malignant glioma. Mol Imaging. 2012; 11(6): 516–27. doi: 10.2310/7290.2012.00022Galldiks N, Dunkl V, Kracht LW, Vollmar S, Jacobs AH, Fink GR, et al. Volumetry of [(1)(1)C]-methionine positron emission tomographic uptake as a prognostic marker before treatment of patients with malignant glioma. Mol Imaging. 2012; 11(6): 516–27. doi: 10.2310/7290.2012.00022Pyka T, Gempt J, Hiob D, Ringel F, Schlegel J, Bette S, et al. Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas. Eur J Nucl Med Mol Imaging. 2016; 43(1): 133–41. doi: 10.1007/s00259-015-3140-4Pyka T, Gempt J, Hiob D, Ringel F, Schlegel J, Bette S, et al. Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas. Eur J Nucl Med Mol Imaging. 2016; 43(1): 133–41. doi: 10.1007/s00259-015-3140-4Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Långström B, et al. Positron emission tomography(11)C- methionine and survival in patients with low-grade gliomas. Cancer. 2001; 92(6): 1541–49. doi: 10.1002/1097-0142(20010915)92: 6<1541: : AID-CNCR1480>3.0.CO; 2-DRibom D, Eriksson A, Hartman M, Engler H, Nilsson A, Långström B, et al. Positron emission tomography(11)C- methionine and survival in patients with low-grade gliomas. Cancer. 2001; 92(6): 1541–49. doi: 10.1002/1097-0142(20010915)92: 6<1541: : AID-CNCR1480>3.0.CO; 2-DFloeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, et al. Prognostic value of O-(2-18Ffluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med. 2007; 48: 519-27. doi: 10.2967/jnumed.106.037895Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, et al. Prognostic value of O-(2-18Ffluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med. 2007; 48: 519-27. doi: 10.2967/jnumed.106.037895Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging. 2012; 39(6): 1021–29. doi: 10.1007/s00259-012-2109-9Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging. 2012; 39(6): 1021–29. doi: 10.1007/s00259-012-2109-9Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, et al. Hot spots in dynamic(18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol. 2011; 13(3): 307–16. doi: 10.1093/neuonc/noq196Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, et al. Hot spots in dynamic(18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol. 2011; 13(3): 307–16. doi: 10.1093/neuonc/noq196Thon N, Kunz M, Lemke L, Jansen NL, Eigenbrod S, Kreth S, et al. Dynamic F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. Int J Cancer. 2015; 136(9): 2132–45. doi: 10.1002/ijc.29259Thon N, Kunz M, Lemke L, Jansen NL, Eigenbrod S, Kreth S, et al. Dynamic F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. Int J Cancer. 2015; 136(9): 2132–45. doi: 10.1002/ijc.29259Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for highgrade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11): 1963–72. doi: 10.1200/JCO.2009.26.3541Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for highgrade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11): 1963–72. doi: 10.1200/JCO.2009.26.3541Santra A, Kumar R, Sharma P, Bal C, Kumar A, Julka PK, et al. F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI. Eur J Radiol. 2012; 81(3): 508–13. doi: 10.1016/j.ejrad.2011.01.080Santra A, Kumar R, Sharma P, Bal C, Kumar A, Julka PK, et al. F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI. Eur J Radiol. 2012; 81(3): 508–13. doi: 10.1016/j.ejrad.2011.01.080Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MM, et al. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med. 2012; 37(2): 158–63. doi: 10.1097/RLU.0b013e318238f51aTripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MM, et al. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med. 2012; 37(2): 158–63. doi: 10.1097/RLU.0b013e318238f51aMinamimoto R, Saginoya T, Kondo C, Tomura N, Ito K, Matsuo Y, et al. Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-Methionine PET: visual assessment versus quantitative assessment. PloS ONE. 2015; 10(7): e0132515. doi: 10.1371/journal.pone.0132515Minamimoto R, Saginoya T, Kondo C, Tomura N, Ito K, Matsuo Y, et al. Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-Methionine PET: visual assessment versus quantitative assessment. PloS ONE. 2015; 10(7): e0132515. doi: 10.1371/journal.pone.0132515Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR Am J Neurorad. 2013; 34(5): 944–50. doi: 10.3174/ajnr.A3324Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR Am J Neurorad. 2013; 34(5): 944–50. doi: 10.3174/ajnr.A3324Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008; 49(5): 694–9. doi: 10.2967/jnumed.107.048082Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008; 49(5): 694–9. doi: 10.2967/jnumed.107.048082Скворцова Т.Ю., Бродская З.Л., Гурчин А.Ф., Савинцева Ж.И. Диагностическая точность ПЭТ с [11С]метиониномSkvortsova TYu, Brodskaya ZL, Gurchin AF, Savintseva ZhI. Diagnostic accuracy of PET using [11C]methionine in differential diagnosis of primary brain tumor recurrence from radiation-induced brain injury. Medical Visualization. 2011; 6: 80–92 (in Russian).в разграничении продолженного роста первичных церебральных опухолей и лучевых поражений головного мозга. Медицинская визуализация. 2011; 6: 80–92.Salber D, Stoffels G, Pauleit D, Reifenberger G, Sabel M, Shah NJ, et al. Differential uptake of [18F]FET and [3H]L-methionine in focal cortical ischemia. Nucl Med Biol. 2006; 33(8): 1029–35. doi: 10.1016/j.nucmedbio.2006.09.004Salber D, Stoffels G, Pauleit D, Reifenberger G, Sabel M, Shah NJ, et al. Differential uptake of [18F]FET and [3H]L-methionine in focal cortical ischemia. Nucl Med Biol. 2006; 33(8): 1029–35. doi: 10.1016/j.nucmedbio.2006.09.004Salber D, Stoffels G, Pauleit D, Oros-Peusquens AM, Shah NJ, Klauth P, et al. Differential uptake of O-(2-18F-fluoroethyl)-L-tyrosine, L-3H-methionine, and 3H-deoxyglucose in brain abscesses. J Nucl Med. 2007; 48(12): 2056–62. doi: 10.2967/jnumed.107.046615Salber D, Stoffels G, Pauleit D, Oros-Peusquens AM, Shah NJ, Klauth P, et al. Differential uptake of O-(2-18F-fluoroethyl)-L-tyrosine, L-3H-methionine, and 3H-deoxyglucose in brain abscesses. J Nucl Med. 2007; 48(12): 2056–62. doi: 10.2967/jnumed.107.046615Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging. 2015; 42(5): 685–95. doi: 10.1007/s00259-014-2959-4Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging. 2015; 42(5): 685–95. doi: 10.1007/s00259-014-2959-4Karunanithi S, Sharma P, Kumar A, Khangembam BC, Bandopadhyaya GP, Kumar R, et al. 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2013; 40(7): 1025–35. doi: 10.1007/s00259-013-2384-0Karunanithi S, Sharma P, Kumar A, Khangembam BC, Bandopadhyaya GP, Kumar R, et al. 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2013; 40(7): 1025–35. doi: 10.1007/s00259-013-2384-0Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004; 31(11): 1464–70. doi: 10.1007/s00259-004-1590-1Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004; 31(11): 1464–70. doi: 10.1007/s00259-004-1590-1Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg. 2003; 98(5): 1056–64. doi: 10.3171/jns.2003.98.5.1056Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg. 2003; 98(5): 1056–64. doi: 10.3171/jns.2003.98.5.1056Galldiks N, Stoffels G, Filss CP, Piroth MD, Sabel M, Ruge MI, et al. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med. 2012; 53(9): 1367–74. doi: 10.2967/jnumed.112.103325Galldiks N, Stoffels G, Filss CP, Piroth MD, Sabel M, Ruge MI, et al. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med. 2012; 53(9): 1367–74. doi: 10.2967/jnumed.112.103325Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AA, Yong WH, Phelps ME, et al. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med. 2014; 55(1): 30–6. doi: 10.2967/jnumed.113.121418Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AA, Yong WH, Phelps ME, et al. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med. 2014; 55(1): 30–6. doi: 10.2967/jnumed.113.121418Cicone F, Minniti G, Romano A, Papa A, Scaringi C, Tavanti F, et al. Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. Eur J Nucl Med Mol Imaging. 2015; 42(1): 103–11. doi: 10.1007/s00259-014-2886-4Cicone F, Minniti G, Romano A, Papa A, Scaringi C, Tavanti F, et al. Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. Eur J Nucl Med Mol Imaging. 2015; 42(1): 103–11. doi: 10.1007/s00259-014-2886-4Skvortsova TYu, Brodskaya ZL, Savintseva ZhI, Gurchin AF. Imaging challenges in the assessment of posttreatment gliomas and opportunities to improve the accuracy of diagnosis using PET with [11C]methionine. Diagnostic Radiology and Radiotherapy. 2014: 5(2): 5–16 (in Russian). doi: 10.22328/2079-5343-2014-2-5-16Скворцова Т.Ю., Бродская З.Л., Савинцева Ж.И., Гурчин А.Ф. Современные проблемы мониторинга лечения церебральных глиом и возможности повышения точности диагностики при ПЭТ с 11С-метионином. Лучевая диагностика и терапия. 2014; 5(2): 5–16. doi: 10.22328/2079-5343-2014-2-5-16.Galldiks N, Langen K, Holy R, Pinkawa M, Stoffels G, Nolte KW, et al. Assessment of treatment response in patients with glioblastoma using [18F]Fluoroethyl-L-Tyrosine PET in comparison to MRI. J Nucl Med. 2012; 53(7): 1048–57. doi: 10.2967/jnumed.111.098590Galldiks N, Langen K, Holy R, Pinkawa M, Stoffels G, Nolte KW, et al. Assessment of treatment response in patients with glioblastoma using [18F]Fluoroethyl-L-Tyrosine PET in comparison to MRI. J Nucl Med. 2012; 53(7): 1048–57. doi: 10.2967/jnumed.111.098590Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G, et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011; 80(1): 176–84. doi: 10.1016/j.ijrobp.2010.01.055Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G, et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011; 80(1): 176–84. doi: 10.1016/j.ijrobp.2010.01.055Popperl G, Goldbrunner R, Gildehaus FJ, Kreth FW, Tanner P, Holtmannspötter M, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2005; 32(9): 1018–25. doi: 10.1007/s00259-005-1819-7Popperl G, Goldbrunner R, Gildehaus FJ, Kreth FW, Tanner P, Holtmannspötter M, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2005; 32(9): 1018–25. doi: 10.1007/s00259-005-1819-7Pöpperl G, Götz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC, et al. Serial O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging. 2006; 33(7): 792–800. doi: 10.1007/s00259-005-0053-7Pöpperl G, Götz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC, et al. Serial O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging. 2006; 33(7): 792–800. doi: 10.1007/s00259-005-0053-7Galldiks N, Kracht LW, Burghaus L, Ullrich RT, Backes H, Brunn A, et al. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging. 2010; 9(1): 40–6. doi: 10.2310/7290.2010.00002Galldiks N, Kracht LW, Burghaus L, Ullrich RT, Backes H, Brunn A, et al. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging. 2010; 9(1): 40–6. doi: 10.2310/7290.2010.00002Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD, et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl.Med Mol Imaging. 2006; 33(5): 516–24. doi: 10.1007/s00259-005-0002-5Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD, et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl.Med Mol Imaging. 2006; 33(5): 516–24. doi: 10.1007/s00259-005-0002-5Galldiks N, Filss CP, Goldbrunner R, Langen KJ. Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET imaging findings in a patient with bevacizumab failure. Case Rep Oncol. 2012; 5(3): 490–4. doi: 10.1159/000342480Galldiks N, Filss CP, Goldbrunner R, Langen KJ. Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET imaging findings in a patient with bevacizumab failure. Case Rep Oncol. 2012; 5(3): 490–4. doi: 10.1159/000342480Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011; 52(6): 856–64. doi: 10.2967/jnumed.110.086645Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011; 52(6): 856–64. doi: 10.2967/jnumed.110.086645Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, et al. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res. 2014; 20(13): 3550–59. doi: 10.1158/1078-0432.CCR-13-1440Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, et al. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res. 2014; 20(13): 3550–59. doi: 10.1158/1078-0432.CCR-13-1440Gneveckow U, Jordan A, Scholz R, Brüss V, Waldöfner N, Ricke J, et al. Description and characterization of the novel hyperthermia- and thermoablation-system MFH 300F for clinical magnetic fluid hyperthermia. Med Phys. 2004; 31(6): 1444– 51. doi: 10.1118/1.1748629Gneveckow U, Jordan A, Scholz R, Brüss V, Waldöfner N, Ricke J, et al. Description and characterization of the novel hyperthermia- and thermoablation-system MFH 300F for clinical magnetic fluid hyperthermia. Med Phys. 2004; 31(6): 1444– 51. doi: 10.1118/1.1748629Plotkin M, Gneveckow U, Meier-Hauff K, Amthauer H, Feussner A, Denecke T, et al. 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastomas. Int J Hyperthermia. 2006; 22(4): 319–25. doi: 10.1080/02656730600734128Plotkin M, Gneveckow U, Meier-Hauff K, Amthauer H, Feussner A, Denecke T, et al. 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastomas. Int J Hyperthermia. 2006; 22(4): 319–25. doi: 10.1080/02656730600734128Herholz K, Coope D, Jackson A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol. 2007; 6(8): 711–24. doi: 10.1016/S1474-4422(07)70192-8Herholz K, Coope D, Jackson A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol. 2007; 6(8): 711–24. doi: 10.1016/S1474-4422(07)70192-8Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010; 9(9): 906–20. doi: 10.1016/S1474-4422(10)70181-2Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010; 9(9): 906–20. doi: 10.1016/S1474-4422(10)70181-2Pauleit D, Langen KJ, Floeth F, Hautzel H, Riemenschneider MJ, Reifenberger G, et al. Can the apparent diffusion coefficient be used as a noninvasive parameter to distinguish tumor tissue from peritumoral tissue in cerebral gliomas. J Magn Reson Imaging. 2004; 20(5): 758–64. doi: 10.1002/jmri.20177Pauleit D, Langen KJ, Floeth F, Hautzel H, Riemenschneider MJ, Reifenberger G, et al. Can the apparent diffusion coefficient be used as a noninvasive parameter to distinguish tumor tissue from peritumoral tissue in cerebral gliomas. J Magn Reson Imaging. 2004; 20(5): 758–64. doi: 10.1002/jmri.20177Stadlbauer A, Prante O, Nimsky C, Salomonowitz E, Buchfelder M, Kuwert T, et al. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med. 2008; 49(5): 721–9. doi: 10.2967/jnumed.107.049213Stadlbauer A, Prante O, Nimsky C, Salomonowitz E, Buchfelder M, Kuwert T, et al. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med. 2008; 49(5): 721–9. doi: 10.2967/jnumed.107.049213Stadlbauer A, Prante O, Nimsky C, Salomonowitz E, Buchfelder M, Kuwert T, et al. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med. 2008; 49(5): 721–9. doi: 10.2967/jnumed.107.049213

The authors declare that there are no conflicts of interest present.